MyelinWatch EL

INDEPENDENT RESEARCH MONITOR

What actually changed in MS myelin-repair research

A restrained, source-transparent view of human trials, negative results and translational work.

Latest important developments

Substantive changes, not a count of publications or repeated press coverage.

PreclinicalPreclinical programmePositive signal

Preclinical

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that loss of endothelial TNFR2 causes fibronectin to accumulate in demyelinated lesions, trapping OPCs and obstructing repair. Systemic fibronectin inhibition restored myelination and clinical remission in EAE and cuprizone models.

What this means clinically

This is a strong new mechanistic target, but there is no human trial or approved medicine for this approach yet.

Source quality: High for a preclinical finding • peer-reviewed primary paper

Peer-reviewed paperPubMed / PNAS ↗
Late preclinicalAnnounced / plannedNo efficacy data yet

Translational

Low-dose theophylline patch receives funding for GMP development and Phase 1 preparation

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to move a low-dose transdermal theophylline patch toward industrial and GMP production and a planned Phase 1 study in healthy volunteers. The approach targets HDAC2 and has a preclinical rationale for myelin repair.

What this means clinically

The funding narrows the translational gap, but Phase 1 is not yet publicly registered and there are no efficacy data in people with MS.

Source quality: Official university update plus peer-reviewed formulation work

University / investigatorJohannes Gutenberg University Mainz ↗
Registered human trialActive, not recruitingNo efficacy data yet

Phase 3 platform

OCTOPUS: the first interim metformin/ALA analysis is scheduled for September 2026

The OCTOPUS Stage 1 analysis in progressive MS will assess metformin and alpha-lipoic acid. In addition to brain-atrophy MRI, the plan now includes EDSS, Timed 25-Foot Walk and 9-Hole Peg Test measures.

What this means clinically

This is one of the nearest important milestones in progressive MS. Stage 1 may decide which arm continues, but it is not a final Phase 3 result.

Source quality: High for trial status • official academic update

University / investigatorOCTOPUS Trial / UCL ↗
Planned / announced human trialAnnounced / plannedRegulatory development

Phase 2 • planned

Lucid-MS: FDA lifts the clinical hold, allowing a planned Phase 2 to move forward

After an earlier clinical hold, the FDA allowed the Lucid-MS IND to proceed. The company plans a randomised, double-blind, placebo-controlled Phase 2 in progressive MS for the PAD2 inhibitor Lucid-21-302.

What this means clinically

This is permission to begin clinical development, not evidence that the drug remyelinates or improves outcomes. As of 16 September 2026, no public Phase 2 registration or recruiting site had been located.

Source quality: Official company SEC filing • not a peer-reviewed efficacy result

Company filingSEC filing / Quantum BioPharma ↗
PreclinicalPreclinical programmePositive signal

Preclinical

CN045 promoted human OPC differentiation and remyelination in mice

An npj Drug Discovery paper described CN045, a CNS-penetrant lead that promoted OPC differentiation and myelin-like ensheathment in human cells in vitro and increased remyelination in a mouse demyelination model.

What this means clinically

This is an interesting drug-development lead, but it remains preclinical. Pharmacokinetic optimisation, toxicology and then human testing are still required.

Source quality: High for a preclinical finding • peer-reviewed primary paper

Peer-reviewed papernpj Drug Discovery ↗
Human safety / PK onlyAnnounced / plannedRegulatory development

Phase 1

PTD802: FDA clearance for the first human study

The FDA cleared the IND for PTD802, an oral selective GPR17 antagonist designed to release a brake on OPC maturation and promote remyelination.

What this means clinically

This is an important step from laboratory work to human testing, but no efficacy data in people with MS are available yet.

Source quality: Official company regulatory announcement • no efficacy data yet

Official programme sourcePheno Therapeutics ↗

EVIDENCE FIRST

See the complete evidence pipeline

Human studies and preclinical work are never blended into one claim.

Pipeline →